Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Investor Presentation (April 2018)
18 slides from Nemaura Medical's investor presentation, Apr 26, 2018
Slide 1: Nemaura Medical Corporate Presentation April 2018
ee WN) NEMAURA MEDICAL NASDAQ: NMRD Better Diagnostics for Life Corporate Presentation April 2018
Slide 2: Forward-looking statements
This presentation includes forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements, such as statements about Nemaura’s short-term and long-term growth strategies, can sometimes be identified by use of terms such as “intend,” “expect,” “plan,” “es
Slide 3: Differentiated product platform; non-invasive glucose monitoring
•Differentiated product platform; potentially disruptive product to traditional blood glucose monitoring technology Technology evolved out of Company’s fundamental expertise in transdermal drug delivery •Non-invasive, flexible and affordable adhesive skin-patch based proprietary platform technology
Slide 4: SugarBEAT device and data display
Full color, high-resolution images of the data, rapidly converted using an algorithm, and displayed in various formats including tabular and graphical, with user-defined alarms for high and low readings. SugarBEAT applied to the skin, containing (i) reusable Bluetooth-enabled transmitter, (ii) recha
Slide 5: BEAT technology platform
Our proprietary BEAT™ technology platform consists of an adhesive daily-disposable skin patch integrated into a reusable Bluetooth-enabled transmitter that collects and quantifies a wide range of analytes present within interstitial fluid. The BEAT™patch extracts glucose from below the skin to an ad
Slide 6: SugarBEAT Glucose Monitoring
SugarBEAT® Glucose Monitoring every 5 mins “* Each disposable skin-patch lasts up to 24 hours “* Finger stick calibration required whenever new patch is affixed “* Transmitter shelf life estimated to be 2 years DINNER DISCONNECTED ) NEMAURA
Slide 7: SugarBEAT commercial launch and CE Mark status
vSugarBEAT® commercial launch expected Q4 2018 in UK vCE Mark granted Q1 2016 on predecessor version (watch format) vCE approval required for wireless version as adjunct device, with European Clinical Trials completed in Q4 2017 and PMA clinical trial targeted to commence in Q4 2018
Slide 8: Current Market
Current Market A large and growing opportunity Dexcom Platinum Global Annual Sales Projected ~S846M in 2018! Abbott Libre Global Annu: ‘Ss Projected ~S1Bn in 2018! Europe Glucose Monitoring Market U.S. Glucose Monitoring Market 30.3 million Total Diabetics” + Representing 9.4% of the population in t
Slide 9: SugarBEAT Market Size by Diabetic Population
SugarBEAT® Market Size by Diabetic Population Target reimbursement for Insulin Dependent Adult Diabetics as low-cost adjunct glucose monitoring solution Target adult cash-payers for non-Insulin Dependent Type I Diabetics Europe 58.0MM Diabetics! 87MM ~ Type + insulin Usa ‘ependent Type? 303MM Diabet
Slide 10: Target Patient Population and Market Penetration
Current Market Target Patient Population aes srg aN Competitor Market Penetration Target Patient Group Market Penetration (US, EU, GCC) Type 1 Insulin-Dependent <1% within 5 years : 1 (Bxomutriveres 2 [EU > 3.77M Type 1] Dexcom: 270K patients after 8 years Up to 15% within 5 years Type 2 Insulin-Dep
Slide 11: SugarBEAT Continuous Glucose Monitoring Competitive Landscape
SugarBEAT® Continuous Glucose Monitoring Competitive Landscape Manufacturer Abbott Dexcom Dexcom Senseonies maura Me Technology Inserted Sensor Inserted Sensor Inserted Sensor Implanted Sensor ion invasive Sensor bene 114% 9.8% 90% 114% Mebaby (Gate Have 99% Not Available 97.0%) 99.1% Grid A+B zone)
Slide 12: Clinical Data
Clinical Data Q4 2017 European Clinical Data Summary, Type | and 2 Diabetics Study Criteria and Performance Metrics The following criteria have been employed to measure the performance of the sugarBEAT® device: meter Reference Device dy 1 Yellow Springs Instrument (YSI) glucose analyser equivalent P
Slide 13: Target patient positioning versus competitors
<1% within 5 years Type 1 Insulin Dependent (~6.5% of diabetics) 1 Most Type 1s on Continuous Glucose Monitoring (CGM) would prefer daily continuous monitoring, therefore Dexcom and Abbott are better choices as finger prick calibration is not required for Dexcom or Libre. 3 Most Type 2s do not use C
Slide 14: Market Launch Strategy
Market Launch Strategy Territory (in order of launch) Launch Plan DBI Jersey — Supply Direct to Market by DJB, Reimbursement/Drug agreement Tariff Listing EU DBI Jersey 50:50 TV Sub-license to Multinationals cece TPMENA ~non-binding rect to Market and Govemment Subsidized letter of intent . Device T
Slide 15: SugarBEAT Milestones
SugarBEAT® Milestones 525 patient day CE clinical trials us Submitted for CE approval UK launch for wireless version launch Major EU markets launch 4Q 2017 1Q 2018 2Q 2018 3Q 2018 4Q 2018 2019 Onwards PMA approval * CE Mark Approval for wireless version ir Manufacturing Development » 525 patient day
Slide 16: SugarBEAT Active R&D Pipeline
SugarBEAT™ Active R&D Pipeline Product Key Features «Include Pediatric Cover SugarBEAT «Increased patch wear time Generation II * - EITHER Further Improved Accuracy (MARD) ' OR + Auto-calibration (no finger stick needed) + Provide glucose monitoring for immobile patients In-Clinic variant of SugarBE
Slide 17: BEAT Platform Future R&D
BEAT™ Platform Future R&D Phenylalanine Prostaglandin Lactate i NEMAURA Projected 30 month development timeframe per analyte Pipeline Uses Diagnostics Phenylalanine reening for inflammatory in formulations during drug and cosmetic development Lactate monitoring in intensive care ‘Monitoring the impa
Slide 18: Intellectual Property
Intellectual Property Expiration Date ich_Granted/ Issued Patent: Cumulative Measurement of an May20, 2032 Austalia, France, Germany, Italy, Poland, Spain, Brazil Canada, China, India, Japan, Qatar, Analyte*. Mis Netherlands, UK United Arab Emirates, U.S. ai, 8 Australia, Germany, France, UK, Italy,